An FDA advisory board recommended withdrawing government approval for the breast cancer drug, Avastin. Pros and cons of the decision and its implications for FDA’s accelerated approval process to treat serious and life threatening diseases.

Guests

  • Gardiner Harris Science reporter for "The New York Times" and author of the mystery novel 'Hazard.'
  • Dr. Carolyn Hendricks A medical oncologist affiliated with Suburban Hospital in Bethesda.
  • William Hubbard Former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA
  • Dr. Peter Bach Attending physician and director of the Center for Health Policy and Outcomes at Memorial Sloan-Kettering Cancer Center, and a former adviser to Medicare.

Topics + Tags

Comments

comments powered by Disqus
Most Recent Shows

The Tuskegee Study, 50 Years Later

Friday, Jul 29 2022Fifty years after the Tuskegee study, Diane talks to Harvard's Evelynn Hammonds about the intersection of race and medicine in the United States, and the lessons from history that can help us understand health inequities today.

Jan. 6 And The Ongoing Threat Of Right-Wing Extremism

Friday, Jul 15 2022What's happened to groups like the Oath Keepers and Proud Boys post-January 6, and the ongoing threat of far-right extremism in this country. Diane talks to Sam Jackson, author of "Oath Keepers: Patriotism and the Edge of Violence in a Right-Wing Antigovernment Group"